Flu :: GSK to supply and store H5N1 vaccine products for US flu pandemic stockpiling
GlaxoSmithKline (NYSE:GSK), one of the world?s largest vaccine manufacturers, today announced it has been awarded a contract to supply pre-pandemic vaccines to the US strategic national stockpile. The company has received an initial $40 million order under the contract from the U.S. Department of Health and Human Services (HHS) for bulk H5N1 antigen – the substance in the vaccines that will help produce an immune response.